Sign in

CIK 0001540159 · Non-accelerated filer<br>Smaller reporting company

Edesa Biotech, Inc.

Sign in to watch
Ticker
EDSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Sep 30
Incorporated
British Columbia, Canada
Entity type
operating
Phone
(905) 475-1234
Business address
C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada, M5H 2T6
Former names
Stellar Biotechnologies, Inc.
  1. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  2. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  3. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  4. SCHEDULE 13G Stake Statement of Beneficial Ownership
  5. 8-K Event Executive or director change
  6. SCHEDULE 13G Stake Statement of Beneficial Ownership
  7. 10-Q Report Quarterly Report
  8. 8-K Event Results of operations
  9. 4 Grant or award Chief Executive Officer acquired 1,159 shares (grant or award)
  10. 4 Grant or award Chief Executive Officer acquired 2,578 shares (grant or award)
  11. ARS Other Annual Report to Security Holders
  12. DEFA14A Proxy Proxy Materials
  13. DEF 14A Proxy Proxy Statement
  14. SCHEDULE 13G Stake Statement of Beneficial Ownership
  15. 4 Open-market buy President bought 2,000 shares at $1.57 ($3,140)
  16. 4 Open-market buy Chief Executive Officer bought 1,000 shares at $6.60 ($6,599)
  17. 4 Open-market buy Chief Executive Officer bought 10,000 shares at $3.90 ($39,000)
  18. 4 Open-market buy Chief Executive Officer bought 10,000 shares at $4.26 ($42,560)
  19. 4 Open-market buy Chief Executive Officer bought 10,000 shares at $3.63 ($36,300)
  20. 4 Open-market buy Chief Executive Officer bought 3,000 shares at an average $2.09 ($6,280)

Page 3 of 38 · 753 filings